



ASX Release

3 July 2025

Acrux receives further \$0.46 million advance on FY25 R&D Tax Incentive

Melbourne, Australia; Acrux Limited (ASX:ACR), a specialty pharma company developing and commercialising a portfolio of topically applied pharmaceutical products, is pleased to announce it has received a second advance from Radium Capital in relation to its FY25 R&D Tax Incentive (RDTI). This second advance totals \$0.46 million and brings the total value of advances secured against FY25 RDTI to \$2.19 million, broadly representing 80% of the estimated RDTI applicable for the eleven months to 31 May 2025.

This short term funding facility has been utilised by Acrux for several years to give early access to the RDTI rebate. The FY25 rebate is expected to be received from the Australian Tax Office later in 2025 and these funds will be used to support the progression of the development products and management of the Company's working capital.

Authorised for release by the Board of Acrux Limited.

About Acrux

Acrux is a specialty pharma company with a successful track record of developing and commercialising a pipeline of topically applied pharmaceutical products. Drawing on 25 years of experience, Acrux has successfully marketed through licensees a number of products worldwide with emphasis on the United States. Acrux is formulating and developing a range of topical generic products by leveraging its highly skilled workforce, on-site laboratories, GMP manufacturing suite, technical, clinical and commercial experience to bring affordable products to market. Acrux encourages collaboration and is well positioned to discuss commercial partnering and product development opportunities. For further information on Acrux, visit: www.acrux.com.au

For more information, please contact:

John Warmbrunn

CEO & Managing Director

Acrux Limited

P: + 61 3 8379 0100

E: john.warmbrunn@acrux.com.au

For personal use only